PLYX
Polaryx Therapeutics, Inc.
Key Financials
Operating Income
$-7821000
↓ 79.7%
Net Income
$-8985000
↑ 70.4%
Total Assets
$5.2M
↑ 3.4%
Total Liabilities
$605000.00
↑ 109.3%
EPS (Diluted)
$-0.20
↑ 77.5%
Shareholders' Equity
$4.6M
↓ 3.1%
Cash & Equivalents
$5.1M
↑ 11.3%
Operating Cash Flow
$-3944000.00
↓ 53.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/13/2026 | View on SEC |
| ARS | 7/28/2026 | View on SEC |
| DEFA14A | 7/28/2026 | View on SEC |
| DEF 14A | 7/28/2026 | View on SEC |
| S-8 | 7/24/2026 | View on SEC |
| 8-K | 7/21/2026 | View on SEC |
| 8-K | 7/17/2026 | View on SEC |
| 4 | 5/28/2026 | View on SEC |
| 8-K | 5/28/2026 | View on SEC |
| 10-Q | 5/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PLYX |
| Company Name | Polaryx Therapeutics, Inc. |
| CIK | 2075320 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | WY |
| Phone | 201-940-7236 |